Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.57 |
| ▸ | RXRA | P19793 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848222 | 1.00 | PPARG (0.57) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848187 | 0.91 | PPARG (0.62) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17859159 | 0.91 | PPARG (0.60) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848299 | 0.91 | PPARG (0.56) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848189 | 0.91 | PPARG (0.62) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848300 | 0.91 | PPARG (0.56) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848278 | 0.90 | CA12 (0.53) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17848275 | 0.90 | CA12 (0.53) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17821315 | 0.90 | PPARG (0.57) | PPARGRXRACA12CA1CA2 | |
| SCHEMBL17821316 | 0.90 | PPARG (0.57) | PPARGRXRACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | claimed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | KRAS, NRAS, HRAS | PPARG 2635/4885RXRA 341/4885CA12 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.